Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 3. Отображено 3.
07-02-2017 дата публикации

Method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5

Номер: US0009562227B2
Автор: Semi Kim, Hee Young Kang, Myoung Suk Choi, Mi-Ra Lee, Jin-San Yoo, Young Kyu Park, KIM SEMI, KANG HEE YOUNG, CHOI MYOUNG SUK, LEE MI-RA, YOO JIN-SAN, PARK YOUNG KYU, Kim Semi, Kang Hee Young, Choi Myoung Suk, Lee Mi-Ra, Yoo Jin-San, Park Young Kyu
Принадлежит: Korea Research Institute of Bioscience & Biotechnology, KIM SEMI, KANG HEE YOUNG, CHOI MYOUNG SUK, LEE MI-RA, YOO JIN-SAN, PARK YOUNG KYU, KOREA RES INST OF BIOSCIENCE & BIOTECHNOLOGY, Kim Semi, Kang Hee Young, Choi Myoung Suk, Lee Mi-Ra, Yoo Jin-San, Park Young Kyu

The present invention relates to a method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5 (ITGA5), more precisely a method for measuring integrin alpha 5 expression pattern in SIP1/ZEB2 over-expressing cell line or SIP1/ZEB2 expression induced cell line, both treated with sample compounds, by comparing with that of the control. The method of the present invention facilitates screening of anticancer agent or SIP1/ZEB2 inhibitor simply by measuring integrin alpha 5 expression, so that it can be effectively applied in the field of medicine.

Подробнее
Номер записи: 1
06-10-2015 дата публикации

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

Номер: US0009150650B2
Автор: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Se-mi Kim, Sang-Seok Koh, YOO JIN-SAN, LEE WEON-SUP, SHIM SANG-RYEOL, PARK MI-HEE, KANG JEONG-EUN, KIM DO-YUN, LEE JOON CHUL, LEE DONG-HEON, CHO TOO-HYON, SUL SAM-SOOK, KWON YOUNG-GUEN, PYUN BO-JEONG, KIM KWI-HWA, YUN CHAE-OK, KIM NAHM-JU, JEON JAE-WON, LEE DONG-SUP, PARK YOUNG-WOO, RHA GEUN-BAE, JANG HYUN-SOOK, YOO HYEON-MI, KIM SUNG-WOO, KIM SE-MI, KOH SANG-SEOK
Принадлежит: PHARMABCINE INC., YOO JIN-SAN, LEE WEON-SUP, SHIM SANG-RYEOL, PARK MI-HEE, KANG JEONG-EUN, KIM DO-YUN, LEE JOON CHUL, LEE DONG-HEON, CHO TOO-HYON, SUL SAM-SOOK, KWON YOUNG-GUEN, PYUN BO-JEONG, KIM KWI-HWA, YUN CHAE-OK, KIM NAHM-JU, JEON JAE-WON, LEE DONG-SUP, PARK YOUNG-WOO, RHA GEUN-BAE, JANG HYUN-SOOK, YOO HYEON-MI, KIM SUNG-WOO, KIM SE-MI, KOH SANG-SEOK, PHARMABCINE INC

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Подробнее
Номер записи: 2
18-12-2008 дата публикации

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

Номер: CA2691159A1
Автор: Bo Jeong Pyun, Chae Ok Yun, Do Yun Kim, Dong Heon Lee, Dong Sup Lee, Geun Bae Rha, Hyeon Mi Yoo, Hyun Sook Jang, Jae Won Jeon, Jeong Eun Kang, Jin San Yoo, Joon Chul Lee, Kwi Hwa Kim, Mi Hee Park, Nahm Ju Kim, Sam Sook Sul, Sang Ryeol Shim, Sang Seok Koh, Semi Kim, Sung Woo Kim, Too Hyon Cho, Weon Sup Lee, Young Guen Kwon, Young Woo Park
Принадлежит: Bo Jeong Pyun, Chae Ok Yun, Do Yun Kim, Dong Heon Lee, Dong Sup Lee, Geun Bae Rha, Hyeon Mi Yoo, Hyun Sook Jang, Jae Won Jeon, Jeong Eun Kang, Jin San Yoo, Joon Chul Lee, Korea Research Institute of Bioscience and Biotechnology, Kwi Hwa Kim, Mi Hee Park, Nahm Ju Kim, Pharmabeine Inc., Sam Sook Sul, Sang Ryeol Shim, Sang Seok Koh, Semi Kim, Sung Woo Kim, Too Hyon Cho, Weon Sup Lee, Young Guen Kwon, Young Woo Park

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Подробнее
Номер записи: 3